Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AACR, AbbVie, abdomen, Abraxane, Accent, accomplished, aEquity, amassed, Anokion, Arranon, Atlantic, Barr, batiraxcept, BeiGene, belief, bid, Biden, border, bowel, Cambridge, CDE, combinatorial, conflict, contradictory, CPA, CRIT, curative, Deloitte, Dentistry, deployed, Dermatology, digest, digestive, Dimension, doubt, Dove, DSMB, eleven, eluxadoline, encompassing, endocrine, energy, Epidemiology, Epizyme, Evelo, Excellence, exocrine, explanatory, Fisher, FORMA, Gettysburg, gland, GlaxoSmithKline, Gleevec, glucagon, Grail, hidden, Ho, Hohnecker, Hohneker, Ib, ID, indeterminate, Inline, insulin, internship, invaded, irritable, ITT, Jersey, John, Kirk, legacy, Leonard, lieu, lifecycle, lying, Mekinist, Metastagen, military, NATO, NC, NCE, NMPA, Overland, oversaw, PA, paragraph, pear, Promacta, radiographic, Raleigh, ramp, retaliatory, run, Rydap, Scott, SEER, shaped, short, Sigurd, stomach, sugar, Sylvant, Synribo, Tafinlar, Tazverik, Thermo, thin, Thirteen, TMO, Toronto, Touche, Treaty, Tykerb, Ultragenyx, unredacted, Votrient, warrant, water, Wellcome, Wilmington, Yale
Filing tables
Filing exhibits
ARAV similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Aravive, Inc.
Houston, Texas
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-239512, No. 333-248612, and No. 333-262020) and Form S-8 (No.333-227865, No. 333-216586, No. 333-210013, No. 333-204178, No. 333-194949, No. 333-230348, No. 333-233866, No. 333-237425, and No. 333-254400) of Aravive, Inc. of our report dated March 31, 2022, relating to the consolidated financial statements, which appears in Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
Raleigh, North Carolina
March 31, 2022